U.S. MARKET FOR

BRACHYTHERAPY PRODUCTS

TABLE OF CONTENTS

Section  Page

1.0  MARKET STATUS, TRENDS AND FORECASTS 1

1.1 INTRODUCTION AND OVERVIEW 1

1.1.1 Implantable Prostate Seeds 1

1.1.2 Effect of Competing Technologies  2

1.1.3 Accelerated Partial Breast Irradiation (APBI)  3

1.1.4 New Breast Brachytherapy Devices  4

1.1.5 Gynecological Applications  6 

1.1.6 Brain Cancer Brachytherapy  6

1.1.7 Endovascular Brachytherapy  7

1.1.8 Irradiated Microsphere Infusion for Liver Cancer  8

1.1.9 Macular Degeneration and Ophthalmic Applications 10

1.1.9.1 Combined Approach with both Brachytherapy and 12

VEGF Drugs

1.1.9.2 Features of the NeoVista Device 12

1.9.1.3 Market for Treating Macular Degeneration   13

1.2 BRACHYTHERAPY MARKET SUMMARY 14

1.2.1 Sales Growth of Brachytherapy Market Segments 16

1.2.2 Comparative Procedure Growth by Product Category 18

1.2.3 Brachytherapy Forecasts Relative to Incidence of Disease 20

TABLE OF CONTENTS

Section  Page

1.3 MARKET ANALYSIS AND SALES FORECASTS 24

      1.3.1 Brachytherapy Prostate Seed Sales by Product Type 29

1.3.2 Analysis of Seed Sales by Manufacturer    32

1.3.3 Brachytherapy Seed Market Forecasts 34

1.4 BREAST CANCER BRACHYTHERAPY  36

1.4.1 Partial Breast Irradiation with MammoSite 37

1.4.2 Second Generation Breast Brachytherapy Devices  37

1.4.3 Market Forecasts for Breast Brachytherapy 39

1.5 GYNECOLOGICAL BRACHYTHERAPY  41

1.5.1 Newly Approved Gynecological Brachytherapy Devices  41

1.5.2 Market Forecasts for Gynecological Brachytherapy  42

1.6 GLIA-SITE BRACHYTHERAPY FOR BRAIN CANCER  42

1.5.1 Options in Treating Malignant Brain Tumors 44

1.5.2 Advantages of Using GliaSite  44

1.5.3 Market Forecasts for GliaSite 45

1.7 IRRADIATED MICROSPHERES FOR LIVER CANCER  47

1.7.1 Microsphere Properties  48

1.7.2 Product Indications  48

1.7.3 Product Pricing and Market Forecasts  49

1.8  ENDOVASCULAR BRACHYTHERAPY MARKET  51

1.8.1 Endovascular Brachytherapy Products 52

1.8.2 Transformation of the Market in 2003 52

1.8.3 Market Projections for Beta-Cath 53

TABLE OF CONTENTS

Section  Page

1.9 MACULAR DEGENERATION BRACHYTHERAPY  53

1.9.1 NeoVista's Vidion System 55

1.9.2 Market Estimates and Forecasts 56

2.0 ANALYSIS OF PROCEDURE VOLUME 59

2.1 INTRODUCTION AND OVERVIEW  59

2.1.1 LDR vs. HDR Considerations 59

2.1.2 Low Energy Beta Source Procedures  60

2.1.3 Trend Lines and Usage Patterns 60

2.2 BRACHYTHERAPY PROCEDURES  61

2.2.1 Categories of Brachytherapy Procedures 61

2.2.2 Forecasts of Brachytherapy Procedures 62

2.3 ANALYSIS OF DATA SOURCES AND METHODOLOGY 65

2.3.1 Sources of Procedure Data 66

2.3.2 Advantages and Limitations of Available Data Bases 67

2.3.2.1 Advantages of Using Existing Data Bases 67

2.3.2.1 Limitations of Some of the Available Data Bases 67

2.3.3 CMS Medicare Data 68